Related Experiment Video
Updated: Jun 10, 2026
07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time
Florence Nadal-Wollbold1, Arnaud Bocquet, Thierry Bourbon
1Centre de Recherche Pierre Fabre, 17, Avenue Jean Moulin, 81106 Castres cedex, France. florence.nadal_wollbold@pierre-fabre.com
European Journal of Pharmacology
|July 27, 2010
Summary
Two novel PAR1 antagonists, ER121958 and SCH203099, demonstrate potent in vitro anti-platelet activity by inhibiting adhesion and aggregation. These compounds show promise for antithrombotic therapies without affecting the coagulation cascade.
Area of Science:
- Pharmacology
- Hematology
- Biochemistry
Background:
- Thrombosis remains a significant clinical challenge, necessitating novel therapeutic strategies.
- Protease-activated receptor 1 (PAR1) antagonists represent a promising class of antithrombotic agents.
- Understanding the efficacy of novel PAR1 antagonists in preclinical models is crucial for drug development.
Purpose of the Study:
- To evaluate the in vitro antithrombotic effects of ER121958 and SCH203099.
- To assess their impact on platelet adhesion, aggregation, and thrombin time.
- To determine the suitability of guinea-pig models for studying PAR1 antagonists.
Main Methods:
- In vitro assessment of platelet adhesion and aggregation induced by SFLLR.
- Determination of IC(50) values for ER121958 and SCH203099.
- Measurement of thrombin time in human and guinea-pig platelets.
Main Results:
- ER121958 and SCH203099 effectively inhibited SFLLR-induced platelet adhesion and aggregation in both human and guinea-pig platelets.
- IC(50) values for ER121958 were significantly lower than for SCH203099, indicating greater potency.
- Neither antagonist prolonged thrombin time, suggesting no impact on the final coagulation pathway.
Conclusions:
- ER121958 and SCH203099 exhibit potent in vitro anti-platelet properties.
- These PAR1 antagonists are effective in models of platelet aggregation and adhesion.
- Guinea-pig models are suitable for studying PAR1 antagonists due to species similarity in response.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...